Net eve ue i c eased 113% to eco d $2.1 millio , with st o g topli e pe fo ma ce la gely due to the sy e gistic me ge with Gummy USA™ i Octobe 2025 a d acquisitio of Ima aïs Beauty i May of this yea . Both added ew p oduct li es a d B2B custome s a d expa ded the compa y’s dist ibutio cha els.
G oss p ofit i c eased 145% to $1.5 millio , with g oss ma gi s i c easi g f om 61.2% to 70.3%.
Net loss totaled $129,000 o ($0.01) pe basic a d diluted sha e, compa ed to et i come of $67,000 o $0.02 pe basic a d diluted sha e i the same yea -ago qua te .
EBITDA i c eased 75% to $169,000, with adj. EBITDA totali g $290,000 o $0.02 pe basic a d diluted sha e (see defi itio s of these o -GAAP te ms a d thei eco ciliatio to GAAP i the sectio , Use of No -GAAP Measu es, below).
I Ap il, Healthy Ext acts’ wholly ow ed subsidia y, Gummy USA, e te ed a U.S. ma ufactu i g pa t e ship with Ima aïs Beauty, the popula pla t-based i gestible beauty a d well ess b a d fou ded by media pe so ality, Somme Ray, a d awa d-wi i g suppleme t i dust y vete a , Aa o Hefte . Ima aïs has b oad dist ibutio ac oss majo U.S. etail cha els, i cludi g Ta get, Ulta Beauty a d Sp outs, as well as ume ous i te atio al outlets.
Ima ais Beauty pa t e ship lau ched with a i itial la ge o de totali g ea ly 4 millio gummies ac oss five existi g SKUs. The o de has begu shippi g to mo e tha 4,000 sto e locatio s atio wide that i clude highly visible isle e d-cap placeme ts.
I May, the ew pa t e ship with Ima ais Beauty t a sfo med i to its acquisitio by Healthy Ext acts, esulti g i Ima ais Beauty becomi g a ew wholly ow ed ope ati g subsidia y. Si ce its fou di g i 2020, Ima aïs Beauty has att acted wo ldwide acclaim a d cou tless loyal custome s a d social media i flue ce s, with the b a d sold wo ldwide th ough thousa ds of etaile locatio s a d o li e. Ima aïs Beauty’s phe ome al success has bee featu ed i majo busi ess publicatio s, i cludi g WWD, Fo bes, Beauty I depe de t, a d E t ep e eu .
Healthy Ext acts’ t a sfo mative st ategic me ge with Gummy USA last fall has co ti ued to add ess the la ge u met eed i the ut aceutical a d pha maceutical i dust y fo p ecisio -dosed gummy ma ufactu i g tech ology, with this ope i g the doo to ew specialized B2B p oduct developme t.
“Ou seco d qua te of 2026 ep ese ted a othe g eat qua te of eco d-setti g eve ues a d ma ket expa sio ,” stated Healthy Ext acts CEO, Do Swa so . “As ou i th co secutive qua te of yea -ove -yea eve ue g owth, ou mome tum has co ti ued to build.
“Ou st o g topli e pe fo ma ce eflects the co ti ued evolutio of ou compa y i to a i dust y leade i ut aceutical i ovatio . The i teg atio of Gummy USA a d Ima ais Beauty has accele ated ou g owth a d expa ded ou p oduct li es a d add essable ma kets. They have also b ought to us ew majo etaile custome s f om a ou d the wo ld. This has esulted i a sig ifica t i c ease i B2B, di ect-to-co sume a d etail sales.
“We have co ti ued to focus o ou lo g-te m st ategic g owth st ategies, with this i cludi g the achieveme t of supe io leade ship i fo mulatio a d ma ufactu i g tech ologies that ta get the high-g owth, high-ma gi Nut a Pha ma a d Health & Beauty secto s.
“We a e e joyi g vast ew oppo tu ities whe e we ca leve age ou st e gths i adva ced fo mulatio s, ma ufactu i g, a d p op ieta y o al delive y tech ologies. We expect these effo ts to be efit f om the st o g i dust y g owth i ou health a d beauty catego y that is expected to top $730 billio this yea . We also see ma y g eat oppo tu ities i the b oade health a d well ess ma kets.
“Ou ew ma ufactu i g pa t e ship with Ima aïs Beauty quickly evolved i to thei acquisitio due to the ma y st o g sy e gies betwee ou two compa ies. Thei adva ced fo mulatio s a e u like a ythi g I’ve see i the gummy ma ket today, while ou p ecisio dosi g tech ology alig s pe fectly with thei commitme t to p emium quality, i ovatio , a d apid global ma ket expa sio .
“We expect Ima aïs’ ma ket each a d etail mome tum to accele ate ou i -house gummy ma ufactu i g output fo the emai de of the yea . To be su e, this is ot o ly fo the beauty a d well ess catego y, but also as we co ti ue to delive the ext ge e atio of fu ctio al a d OTC gummy delive y systems ac oss multiple catego ies withi ou la ge co sume health ma ket.
“We see ou st o g esults fo the seco d qua te as just the begi i g of a highly scalable, t a sfo matio al g owth phase fo Healthy Ext acts. By leve agi g ou adva ced U.S. ma ufactu i g capabilities, we believe we have a t eme dous oppo tu ity to expa d ou b a d p ese ce wo ldwide.
“Give ou ma y comme cial i itiatives, which i cludes ew B2B custome e gageme t a d p oduct developme t, we co ti ue to believe we have the pote tial to achieve a ualized et eve ue of mo e tha $20 millio by yea e d o up 3x ove last yea . While this aspi atio al goal is agg essive, we believe it is suppo ted by ou cu e t sales pipeli e a d existi g ma ufactu i g a d dist ibutio capacity.
“We see the key to achievi g ou goals will be ou u ique p ecisio dose ma ufactu i g capabilities a d exclusive lice sed delive y systems. We believe these two facto s p ovide exceptio al diffe e tiatio withi ou Nut aceutical, Nut a Pha ma a d Fu ctio al Well ess ma kets, a d they have set the stage fo a exceptio ally st o g pe iod ahead.
“Gummy USA a d Ima aïs Beauty have joi ed us du i g a pe iod of i c eased i vesto i te est a d co solidatio withi the gummy a d well ess secto . Ma y high-p ofile i dust y deals, such as the ece t $1.2 billio acquisitio of G ü s Gummies by U ileve , highlight the ma ket dema d fo scalable well ess b a ds, a d especially those that possess st o g co sume e gageme t, diffe e tiated p oduct positio i g, a d g owi g etail dist ibutio .
“As we look to the seco d half of the yea a d beyo d, ou missio is clea : build o e of the most t usted, i ovative, a d espected health, well ess a d beauty compa ies i the wo ld, while delive i g sustai able lo g-te m value to ou stakeholde s. We welcome you to joi us o this exciti g jou ey.”
Net eve ue i c eased 113% to eco d $2.1 millio f om $969,000 i the seco d qua te of 2025. The i c ease was la gely due to the sy e gistic me ge with Gummy USA™ i Octobe 2025 a d the acquisitio of Ima aïs Beauty i May of this yea which added ew p oduct li es a d B2B custome s a d expa ded the compa y’s dist ibutio cha els. The compa y expects et eve ue g owth to i c ease as its di ect co sume sales a d ma keti g effo ts co ti ue to pe fo m.
G oss p ofit i c eased 145% to $1.5 millio o 70.3% of et eve ue, compa ed to $593,000 o 61.2% of et eve ue i the same yea -ago qua te . The i c ease i g oss p ofit was due to g eate sales a d highe ma gi s e abled by the me ge with Gummy USA a d acquisitio of Ima aïs Beauty.
Ope ati g expe ses i c eased 115% to $1.5 millio compa ed to $699,000 i the same yea -ago qua te . The i c ease was due i pa t to additio al sala ies a d wages associated with the additio of Gummy USA a d Ima aïs Beauty as well as a i c ease i stock-based compe satio expe se.
Net loss totaled $129,000 o ($0.01) pe basic a d diluted sha e, compa ed to et i come of $67,000 o $0.02 pe basic a d diluted sha e i the same yea -ago qua te . The i c ease i et loss was la gely due to i c eased i te est expe se, cha ge i the fai value of de ivatives, a d i c eased G&A expe se elated to the additio of Gummy USA a d Ima aïs Beauty.
EBITDA i c eased 75% to $169,000 f om $97,000 i the same yea -ago qua te .
Adjusted EBITDA, which adjusts additio ally fo o -cash stock-based expe se a d cha ge i fai value of de ivatives, totaled $290,000 o $0.02 pe basic a d diluted sha e, compa ed to a adjusted EBITDA loss of $25,000 o ($0.01) pe basic a d diluted sha e i the same yea -ago qua te .
Cash totaled $190,000 at Ju e 30, 2026, up f om $147,000 at Decembe 31, 2025, with the i c ease p ima ily due to cash ge e ated by ope atio s a d fi a ci gs.
Healthy Ext acts I c. (OTCQB:HYEX) is a leade i ut aceutical i ovatio , p ecisio -dose o al delive y systems, a d fu ctio al well ess co sume b a ds. The compa y develops, ma ufactu es, a d ma kets scie ce-based p oducts focused o beauty, well ess, b ai , hea t, gut, a d lifestyle health th ough p op ieta y fo mulatio s, adva ced delive y tech ologies, a d scalable atio al etail dist ibutio .
Th ough its acquisitio of Ima aïs Beauty, the celeb ity-fou ded i gestible beauty a d well ess b a d co-fou ded by Somme Ray a d e t ep e eu Aa o Hefte , Healthy Ext acts has sig ifica tly expa ded its positio withi the apidly g owi g global beauty a d pe so al ca e ma ket. Ima aïs Beauty combi es adva ced fu ctio al beauty fo mulatio s with st o g co sume e gageme t, i flue ce -d ive b a di g, a d expa di g global etail dist ibutio ac oss majo etail, i cludi g Ta get, Ulta Beauty, No dst om, a d Sp outs, a d i te atio al ma kets.
Healthy Ext acts’ wholly ow ed subsidia y, Gummy USA™, is a leadi g develope a d ma ufactu e of p ecisio -dosed ut aceutical a d pha maceutical-g ade gummies. P op ieta y, pate t-pe di g Su eDose™ tech ology is desig ed to delive supe io dosi g accu acy, safety, efficacy, a d co sume complia ce fo both compa y-ow ed a d pa t e b a ds.
The compa y’s po tfolio also i cludes Be gametNA™ a d Ultimate B ai Nut ie ts™ (UBN™) which offe scie ce-backed suppleme ts suppo ti g ca diovascula a d cog itive health. Healthy Ext acts additio ally mai tai s exclusive ag eeme ts fo i ovative o al delive y tech ologies, i cludi g Gelteq gel delive y systems a d the Gut Health St aw platfo m, which a e desig ed to imp ove bioavailability a d co sume co ve ie ce.
To lea mo e, visit Healthy Ext acts I c., Ima aïs Beauty, Be gametNA, Ultimate B ai Nut ie ts, o Gummy USA.
This p ess elease co tai s fi a cial measu es that a e ot ecog ized measu es u de accou ti g p i ciples ge e ally accepted i the U ited States of Ame ica (“GAAP”), which may i clude EBITDA, adjusted EBITDA a d o -GAAP et i come as defi ed below fo the pu pose of this p ess elease.
EBITDA is defi ed as et i come befo e i come tax expe se, i te est expe se ( et of i te est i come), dep eciatio a d amo tizatio . Adjusted EBITDA is defi ed as EBITDA excludi g the gai o loss elated to stock-based optio /wa a t expe se, stock issued fo se vices, cha ge i fai value of de ivative, offe i g costs, a d M&A- elated expe se. No -GAAP et i come excludes i te est expe se ( et of i te est i come), dep eciatio , amo tizatio a d stock-based expe ses (stock-based optio /wa a t expe se a d stock issued fo se vices), a d M&A- elated expe se.
Healthy Ext acts’ ma ageme t believes that EBITDA, adjusted EBITDA, a d o -GAAP et i come a e useful suppleme tal measu es of the compa y’s ope ati g pe fo ma ce a d ca p ovide i vesto s mea i gful measu es of ove all co po ate pe fo ma ce. EBITDA is also p ese ted because ma ageme t believes that it is f eque tly used by i vestme t a alysts, i vesto s, a d othe i te ested pa ties as a measu e of fi a cial pe fo ma ce. Adjusted EBITDA a d o -GAAP et i come a e also p ese ted because ma ageme t believes that it p ovides i vesto s additio al measu es of the compa y’s co e busi ess. Howeve , such o -GAAP measu es do ot have a sta da dized mea i g p esc ibed by GAAP, a d i vesto s a e cautio ed that such o -GAAP measu es should ot be co st ued as a alte ative to et i come o loss o othe i come stateme t data (which a e dete mi ed i acco da ce with GAAP) as a i dicato of ou pe fo ma ce o as a measu e of liquidity a d cash flows. Ma ageme t’s method of calculati g EBITDA, adjusted EBITDA, a d o -GAAP et i come may diffe mate ially f om the method used by othe compa ies a d acco di gly may ot be compa able to simila ly titled measu es used by othe compa ies.
A eco ciliatio of EBITDA a d adjusted EBITDA to et i come, the most compa able GAAP measu e, is i cluded i the table below. The calculatio of o -GAAP et i come is de ived f om the amou ts p ese ted i this table. Fo the weighted ave age umbe of commo sha es used fo the dete mi atio of adjusted EBITDA a d o -GAAP i come basic a d diluted ea i gs pe commo sha e, see the table, Co solidated Stateme t of Ope atio s, fu the below.
The p elimi a y u audited esults p ese ted i this p ess elease a e estimates o ly a d a e subject to evisio u til the compa y officially epo ts its full seco d qua te esults a d files it Fo m 10-Q with the U.S. Secu ities a d Excha ge Commissio (SEC).
All stateme ts othe tha stateme ts of histo ical facts i cluded i this p ess elease a e “fo wa d-looki g stateme ts” (as defi ed i the P ivate Secu ities Litigatio Refo m Act of 1995). Such fo wa d-looki g stateme ts i clude ou expectatio s a d those stateme ts that use fo wa d-looki g wo ds such as “p ojected,” “expect,” “possibility” a d “a ticipate.” The achieveme t o success of the matte s cove ed by such fo wa d-looki g stateme ts i volve sig ifica t isks, u ce tai ties a d assumptio s. Actual esults could diffe mate ially f om cu e t p ojectio s o implied esults. I vesto s should ead the isk facto s set fo th i the Compa y’s A ual Repo t o Fo m 10-K filed with the SEC o Ap il 8, 2026, a d futu e pe iodic epo ts filed with the U.S. Secu ities a d Excha ge Commissio (SEC). All of the Compa y’s fo wa d-looki g stateme ts a e exp essly qualified by all such isk facto s a d othe cautio a y stateme ts. The Compa y cautio s that stateme ts a d assumptio s made i this ews elease co stitute fo wa d-looki g stateme ts a d make o gua a tee of futu e pe fo ma ce. Fo wa d-looki g stateme ts a e based o estimates a d opi io s of ma ageme t at the time stateme ts a e made. The i fo matio set fo th he ei speaks o ly to the date he eof. The Compa y a d its ma ageme t u de take o obligatio to evise these stateme ts followi g the date of this ews elease.
The p oducts a d fo mulatio s featu ed i this elease a e ot fo use by o sale to pe so s u de the age of 12. This p oduct should be used o ly as di ected o the label. Co sult with a physicia befo e use if you have a se ious medical co ditio o use p esc iptio medicatio s. A docto ‘s advice should be sought befo e usi g this a d a y suppleme tal dieta y p oduct. These stateme ts have ot bee evaluated by the FDA. This p oduct is ot i te ded to diag ose, t eat, cu e o p eve t a y disease.
Gummy USA ™, Be gametNA™, Ultimate B ai Nut ie ts™, UBN™, Cit us Be gamot Supe F uit™ a d F4T® a e t adema ks a d egiste ed t adema ks of Healthy Ext acts™ I c.
Do Swa so , CEOHealthy Ext acts I c.Tel (801) 232-0753Email co tact
Reve ue | $ | 2,067,212 | $ | 968,656 | $ | 3,677,956 | $ | 1,899,935 | Cost of goods sold | 614,768 | 375,828 | 1,236,811 | 882,123 | Ge e al a d admi ist ative | 1,501,206 | 698,434 | 2,818,116 | 1,232,267 | I te est expe se, et of i te est i come | (106,632 | ) | (29,259 | ) | (191,538 | ) | (63,817 | ) | Gai /loss of fo eig t a sactio s | 4,966 | – | 4,966 | – |
The accompa yi g otes a e a i teg al pa t of these u audited co solidated fi a cial stateme ts
Cash | $ | 189,958 | $ | 146,935 | I ve to y, et | 644,114 | 843,357 | Offe i g costs | 149,274 | 149,274 | 1,679,466 | 1,327,317 | Fixed assets | 3,884,990 | 4,233,083 | Goodwill | 26,056,515 | 21,123,922 | Right of use asset, et – o -cu e t | 423,438 | 513,929 | Accou ts payable | 340,515 | 108,496 | Acc ued i te est payable – elated pa ty | 116,113 | 76,401 | Lease liabilities – cu e t | 196,815 | 171,930 | Notes payable – elated pa ty – cu e t | 6,209,827 | 676,250 | 8,389,085 | 1,763,169 | Lease liabilities – lo g-te m | 229,110 | 344,265 | Notes payable – elated pa ty – o -cu e t | 125,276 | 156,835 | De ivative liabilities | 48,353 | 352,411 | P efe ed stock, $0.001 pa value, 75,000,000 sha es autho ized, o sha es issued a d outsta di g, espectively | – | – | Additio al paid-i capital | 46,410,732 | 43,788,013 | Accumulated deficit | (20,450,948 | ) | (20,121,462 | ) |
